Structure-Function Properties of Hemp Seed Proteins and Protein-Derived Acetylcholinesterase-Inhibitory Peptides
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Novel Neuroprotective Compunds for Use in Parkinson's Disease
Novel neuroprotective compounds for use in Parkinson’s disease A thesis submitted to Kent State University in partial Fulfillment of the requirements for the Degree of Master of Science By Ahmed Shubbar December, 2013 Thesis written by Ahmed Shubbar B.S., University of Kufa, 2009 M.S., Kent State University, 2013 Approved by ______________________Werner Geldenhuys ____, Chair, Master’s Thesis Committee __________________________,Altaf Darvesh Member, Master’s Thesis Committee __________________________,Richard Carroll Member, Master’s Thesis Committee ___Eric_______________________ Mintz , Director, School of Biomedical Sciences ___Janis_______________________ Crowther , Dean, College of Arts and Sciences ii Table of Contents List of figures…………………………………………………………………………………..v List of tables……………………………………………………………………………………vi Acknowledgments.…………………………………………………………………………….vii Chapter 1: Introduction ..................................................................................... 1 1.1 Parkinson’s disease .............................................................................................. 1 1.2 Monoamine Oxidases ........................................................................................... 3 1.3 Monoamine Oxidase-B structure ........................................................................... 8 1.4 Structural differences between MAO-B and MAO-A .............................................13 1.5 Mechanism of oxidative deamination catalyzed by Monoamine Oxidases ............15 1 .6 Neuroprotective effects -
Treatment Protocol Copyright © 2018 Kostoff Et Al
Prevention and reversal of Alzheimer's disease: treatment protocol Copyright © 2018 Kostoff et al PREVENTION AND REVERSAL OF ALZHEIMER'S DISEASE: TREATMENT PROTOCOL by Ronald N. Kostoffa, Alan L. Porterb, Henry. A. Buchtelc (a) Research Affiliate, School of Public Policy, Georgia Institute of Technology, USA (b) Professor Emeritus, School of Public Policy, Georgia Institute of Technology, USA (c) Associate Professor, Department of Psychiatry, University of Michigan, USA KEYWORDS Alzheimer's Disease; Dementia; Text Mining; Literature-Based Discovery; Information Technology; Treatments Prevention and reversal of Alzheimer's disease: treatment protocol Copyright © 2018 Kostoff et al CITATION TO MONOGRAPH Kostoff RN, Porter AL, Buchtel HA. Prevention and reversal of Alzheimer's disease: treatment protocol. Georgia Institute of Technology. 2018. PDF. https://smartech.gatech.edu/handle/1853/59311 COPYRIGHT AND CREATIVE COMMONS LICENSE COPYRIGHT Copyright © 2018 by Ronald N. Kostoff, Alan L. Porter, Henry A. Buchtel Printed in the United States of America; First Printing, 2018 CREATIVE COMMONS LICENSE This work can be copied and redistributed in any medium or format provided that credit is given to the original author. For more details on the CC BY license, see: http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License<http://creativecommons.org/licenses/by/4.0/>. DISCLAIMERS The views in this monograph are solely those of the authors, and do not represent the views of the Georgia Institute of Technology or the University of Michigan. This monograph is not intended as a substitute for the medical advice of physicians. The reader should regularly consult a physician in matters relating to his/her health and particularly with respect to any symptoms that may require diagnosis or medical attention. -
WO 2016/001643 Al 7 January 2016 (07.01.2016) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/001643 Al 7 January 2016 (07.01.2016) P O P C T (51) International Patent Classification: (74) Agents: GILL JENNINGS & EVERY LLP et al; The A61P 25/28 (2006.01) A61K 31/194 (2006.01) Broadgate Tower, 20 Primrose Street, London EC2A 2ES A61P 25/16 (2006.01) A61K 31/205 (2006.01) (GB). A23L 1/30 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/GB20 15/05 1898 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (22) International Filing Date: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 29 June 2015 (29.06.2015) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (25) Filing Language: English KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (26) Publication Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (30) Priority Data: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 141 1570.3 30 June 2014 (30.06.2014) GB TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 1412414.3 11 July 2014 ( 11.07.2014) GB (84) Designated States (unless otherwise indicated, for every (71) Applicant: MITOCHONDRIAL SUBSTRATE INVEN¬ kind of regional protection available): ARIPO (BW, GH, TION LIMITED [GB/GB]; 39 Glasslyn Road, London GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, N8 8RJ (GB). -
WO 2014/125397 Al 21 August 2014 (21.08.2014) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization II International Bureau (10) International Publication Number (43) International Publication Date WO 2014/125397 Al 21 August 2014 (21.08.2014) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07D 513/04 (2006.01) A61P 3/10 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 31/542 (2006.01) A61P 25/28 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/IB2014/058777 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 4 February 2014 (04.02.2014) TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 61/765,283 15 February 2013 (15.02.2013) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, New York, New York 10017 (US). -
(12) Patent Application Publication (10) Pub. No.: US 2012/0157420 A1 Schneider (43) Pub
US 2012O157420A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0157420 A1 Schneider (43) Pub. Date: Jun. 21, 2012 (54) TREATMENT AND PREVENTION OF A 6LX 3L/505 (2006.01) SECONDARY INTURY AFTER TRAUMA OR A6IP 29/00 (2006.01) DAMAGE TO THE CENTRAL NERVOUS A6II 3/47 (2006.01) SYSTEM A6IP 25/00 (2006.01) A6IP3/06 (2006.01) (76) Inventor: Eric B Schneider, Glen Arm, MD A6IP 9/00 (2006.01) (US) A6IP 25/22 (2006.01) A6IP 25/24 (2006.01) (21) Appl. No.: 13/392,371 A63L/366 (2006.01) A6II 3/40 (2006.01) (22) PCT Filed: Aug. 31, 2010 (52) U.S. Cl. ......... 514/171; 514/460, 514/419:514/510; (86). PCT No.: PCT/US 10/472O6 514/277; 514/275: 514/423: 514/311 S371 (c)(1), (57) ABSTRACT (2), (4) Date: Feb. 24, 2012 A method of administering one or multiple medications to human patients with CNS injury through oral or parenteral Related U.S. Application Data (including transdermal, intravenous, Subcutaneous, intra (60) Provisional application No. 61/238,453, filed on Aug. muscular) routes. Inflammatory and immunological pro 31, 2009. cesses have been shown to cause secondary damage to CNS s tissues in individuals with acute CNS injury. The present O O invention administers one or more of the following medica Publication Classification tions, which have properties that mitigate the inflammatory (51) Int. Cl. and immunological processes that lead to secondary CNS A6 IK3I/56 (2006.01) damage, via trans-dermal absorption: a statin compound A6 IK 3/405 (2006.01) (e.g., a HMG-CoA reductase inhibitor), a progesterone com A6 IK 3L/25 (2006.01) pound, or a cholinesterase inhibiting compound, among oth A6 IK 3/448 (2006.01) ers, either alone or in combination with other compounds. -
Biochemical Aspects of Seeds from Cannabis Sativa L. Plants Grown In
www.nature.com/scientificreports OPEN Biochemical aspects of seeds from Cannabis sativa L. plants grown in a mountain environment Chiara Cattaneo1*, Annalisa Givonetti1, Valeria Leoni2,3, Nicoletta Guerrieri4, Marcello Manfredi5, Annamaria Giorgi2,3 & Maria Cavaletto1 Cannabis sativa L. (hemp) is a versatile plant which can adapt to various environmental conditions. Hempseeds provide high quality lipids, mainly represented by polyunsaturated acids, and highly digestible proteins rich of essential aminoacids. Hempseed composition can vary according to plant genotype, but other factors such as agronomic and climatic conditions can afect the presence of nutraceutic compounds. In this research, seeds from two cultivars of C. sativa (Futura 75 and Finola) grown in a mountain environment of the Italian Alps were analyzed. The main purpose of this study was to investigate changes in the protein profle of seeds obtained from such environments, using two methods (sequential and total proteins) for protein extraction and two analytical approaches SDS-PAGE and 2D-gel electrophoresis, followed by protein identifcation by mass spectrometry. The fatty acids profle and carotenoids content were also analysed. Mountain environments mainly afected fatty acid and protein profles of Finola seeds. These changes were not predictable by the sole comparison of certifed seeds from Futura 75 and Finola cultivars. The fatty acid profle confrmed a high PUFA content in both cultivars from mountain area, while protein analysis revealed a decrease in the protein content of Finola seeds from the experimental felds. Cannabis sativa L. (hemp) is an annual plant belonging to the family of Cannabaceae. C. sativa is naturally dioe- cious, however this plant has been domesticated by humans since the prehistoric era and monoecious varieties have been selected to obtain higher quality fbers and to optimize seed harvest procedures1. -
Caffeine Analogues and Their Evaluation As Inhibitors of Monoamine Oxidase And
Syntheses of 8-(phenoxymethyl)caffeine analogues and their evaluation as inhibitors of monoamine oxidase and as antagonists of the adenosine A2A receptor. Rozanne Harmse B.Pharm Dissertation submitted in partial fulfilment of the requirements for the degree Magister Scientiae, in Pharmaceutical Chemistry at the North-West University, Potchefstroom Campus. Supervisor: Prof. G. Terre’Blanche Co-Supervisor: Dr. A. Petzer 2013 Potchefstroom 1 TABLE OF CONTENTS ABSTRACT ................................................................................................................................................. IV UITTREKSEL ............................................................................................................................................. VII ACKNOWLEDGEMENTS ........................................................................................................................... X CHAPTER 1 ................................................................................................................................................... 1 INTRODUCTION AND OBJECTIVES .......................................................................................................... 1 1.1 INTRODUCTION .......................................................................................................................................... 1 1.2 RATIONALE ............................................................................................................................................... 4 1.3 HYPOTHESIS ............................................................................................................................................. -
Lessons Learned
Prevention and Reversal of Chronic Disease Copyright © 2019 RN Kostoff PREVENTION AND REVERSAL OF CHRONIC DISEASE: LESSONS LEARNED By Ronald N. Kostoff, Ph.D., School of Public Policy, Georgia Institute of Technology 13500 Tallyrand Way, Gainesville, VA, 20155 [email protected] KEYWORDS Chronic disease prevention; chronic disease reversal; chronic kidney disease; Alzheimer’s Disease; peripheral neuropathy; peripheral arterial disease; contributing factors; treatments; biomarkers; literature-based discovery; text mining ABSTRACT For a decade, our research group has been developing protocols to prevent and reverse chronic diseases. The present monograph outlines the lessons we have learned from both conducting the studies and identifying common patterns in the results. The main product of our studies is a five-step treatment protocol to reverse any chronic disease, based on the following systemic medical principle: at the present time, removal of cause is a necessary, but not necessarily sufficient, condition for restorative treatment to be effective. Implementation of the five-step treatment protocol is as follows: FIVE-STEP TREATMENT PROTOCOL TO REVERSE ANY CHRONIC DISEASE Step 1: Obtain a detailed medical and habit/exposure history from the patient. Step 2: Administer written and clinical performance and behavioral tests to assess the severity of symptoms and performance measures. Step 3: Administer laboratory tests (blood, urine, imaging, etc) Step 4: Eliminate ongoing contributing factors to the chronic disease Step 5: Implement treatments for the chronic disease This individually-tailored chronic disease treatment protocol can be implemented with the data available in the biomedical literature now. It is general and applicable to any chronic disease that has an associated substantial research literature (with the possible exceptions of individuals with strong genetic predispositions to the disease in question or who have suffered irreversible damage from the disease). -
Design, Synthesis and Evaluation of Indole Derivatives As
Design, Synthesis and Evaluation of Indole Derivatives as Multifunctional Agents against Alzheimer’s disease. Ireen Denya (BPharm) Dissertation submitted in partial fulfilment of the requirements for the degree Magister Scientae in Pharmaceutical Chemistry, School of Pharmacy University of the Western Cape Supervisor: Prof. J. Joubert Co – supervisor: Prof. S. F. Malan Bellville July 2017 To my parents Peter and Theodora Denya, And my sisters Ivy, Idah and Tracy Denya. http://etd.uwc.ac.za/ ABSTRACT Alzheimer’s disease (AD) is an age related neurodegenerative disorder characterised by progressive memory loss and cognitive impairment. It is one of several neurodegenerative disorders occurring as a result of a process of programmed cell death known as apoptosis. The process is set off by various stimuli in numerous pathways that ultimately lead to apoptosis. AD stands out as one of the leading causes of death in the elderly in today’s society. The cholinergic hypothesis of AD states that there is an extensive loss of cholinergic neurons in the central nervous system that contributes to cognitive impairment. Acetylcholinesterase inhibitors decrease the breakdown of the neurotransmitter acetylcholine to maintain its post synaptic levels and compensate for the loss of functional brain cells. Amyloid β plaque formation has been shown to be extensively involved in the pathogenesis of AD. The abnormal regulation of the amyloid precursor protein gives rise to plaques that impair neuronal homeostasis and eventually lead to apoptosis. The monoamine oxidase enzymes catalyse the hydrolysis of amine neurotransmitters such as dopamine. The process produces peroxides that cause oxidative stress alongside the depletion of neurotransmitters. -
Perspectives for New and More Efficient Multifunctional Ligands For
molecules Review Perspectives for New and More Efficient 0 Multifunctional Ligands for Alzheimer s Disease Therapy Agnieszka Zagórska 1,* and Anna Jaromin 2 1 Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland 2 Department of Lipids and Liposomes, Faculty of Biotechnology, University of Wroclaw, Wroclaw, 50-383 Wrocław, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-12-620-5456 Academic Editor: Barbara Malawska Received: 29 June 2020; Accepted: 21 July 2020; Published: 23 July 2020 Abstract: Despite tremendous research efforts at every level, globally, there is still a lack of effective drugs for the treatment of Alzheimer0s disease (AD). The biochemical mechanisms of this devastating neurodegenerative disease are not yet clearly understood. This review analyses the relevance of multiple ligands in drug discovery for AD as a versatile toolbox for a polypharmacological approach to AD. Herein, we highlight major targets associated with AD, ranging from acetylcholine esterase (AChE), beta-site amyloid precursor protein cleaving enzyme 1 (BACE-1), glycogen synthase kinase 3 beta (GSK-3β), N-methyl-d-aspartate (NMDA) receptor, monoamine oxidases (MAOs), metal ions in the brain, 5-hydroxytryptamine (5-HT) receptors, the third subtype of histamine receptor (H3 receptor), to phosphodiesterases (PDEs), along with a summary of their respective relationship to the disease network. In addition, a multitarget strategy for AD is presented, based on reported milestones in this area and the recent progress that has been achieved with multitargeted-directed ligands (MTDLs). Finally, the latest publications referencing the enlarged panel of new biological targets for AD related to the microglia are highlighted. -
Hemp: a Composition Review Plus
HEMP: A COMPOSITION REVIEW PLUS By Agustin Gonzalo Miguel Garcia (Fall quarter) A Senior Project submitted In partial fulfillment of the requirements for the degree of Bachelor of Science in Nutrition Food Science and Nutrition Department California Polytechnic State University San Luis Obispo, CA January 2017 Garcia, Agustin G.M.. Hemp: a composition review plus (2017). Senior project for B.S. Nutrition at Cal Poly San Luis Obispo. San Luis Obispo, CA. Hemp has been utilized by many societies around the world yet is currently absent in U.S. food production. The paper described and assessed various sources to aggregate hemp seed composition data and to decipher hemp seed consumption effect on health. There are copious components in hemp seeds that are discussed; some beneficial to human health as well as some antinutritional components that interfere. Numerous articles were analyzed and aspects of each were compiled to provide a source to assess the effectiveness of hemp seed as a nutritious source. Many components found in hemp seeds are found to be beneficial to human health and discussed in detail; from high amounts of polyunsaturated fatty acids (PUFA), to complete, digestible proteins, to present micronutrients and to the “contaminant” cannabinoids. Hemp contains many nutriments that could help nourish a healthy nation and combat this nation’s diet-related disease problem, plus the plant easy to grow and can be beneficial to the environment. This paper demonstrates the multi-purposefulness of hemp and how it can be utilized beyond production of hemp seeds. Hemp: A Composition Review Plus Introduction The effect of polyunsaturated fatty acids (PUFA) on health (especially when replacing saturated fatty acids [SAFA] for PUFA) has been extensively studied to suggest that they provide beneficial effects on health (Zock P. -
Botulinum Toxin
Botulinum toxin From Wikipedia, the free encyclopedia Jump to: navigation, search Botulinum toxin Clinical data Pregnancy ? cat. Legal status Rx-Only (US) Routes IM (approved),SC, intradermal, into glands Identifiers CAS number 93384-43-1 = ATC code M03AX01 PubChem CID 5485225 DrugBank DB00042 Chemical data Formula C6760H10447N1743O2010S32 Mol. mass 149.322,3223 kDa (what is this?) (verify) Bontoxilysin Identifiers EC number 3.4.24.69 Databases IntEnz IntEnz view BRENDA BRENDA entry ExPASy NiceZyme view KEGG KEGG entry MetaCyc metabolic pathway PRIAM profile PDB structures RCSB PDB PDBe PDBsum Gene Ontology AmiGO / EGO [show]Search Botulinum toxin is a protein and neurotoxin produced by the bacterium Clostridium botulinum. Botulinum toxin can cause botulism, a serious and life-threatening illness in humans and animals.[1][2] When introduced intravenously in monkeys, type A (Botox Cosmetic) of the toxin [citation exhibits an LD50 of 40–56 ng, type C1 around 32 ng, type D 3200 ng, and type E 88 ng needed]; these are some of the most potent neurotoxins known.[3] Popularly known by one of its trade names, Botox, it is used for various cosmetic and medical procedures. Botulinum can be absorbed from eyes, mucous membranes, respiratory tract or non-intact skin.[4] Contents [show] [edit] History Justinus Kerner described botulinum toxin as a "sausage poison" and "fatty poison",[5] because the bacterium that produces the toxin often caused poisoning by growing in improperly handled or prepared meat products. It was Kerner, a physician, who first conceived a possible therapeutic use of botulinum toxin and coined the name botulism (from Latin botulus meaning "sausage").